Christofides, Anthos
Katopodi, Xanthi-Lida
Cao, Carol
Karagkouni, Dimitra
Aliazis, Konstantinos http://orcid.org/0000-0003-1954-7914
Yenyuwadee, Sasitorn
Aksoylar, Halil-Ibrahim
Pal, Rinku
Mahmoud, Mohamed A. A.
Strauss, Laura
Tijaro-Ovalle, Natalia M.
Boon, Louis
Asara, John
Vlachos, Ioannis S.
Patsoukis, Nikolaos
Boussiotis, Vassiliki A. http://orcid.org/0000-0002-3963-1518
Funding for this research was provided by:
Foundation for the National Institutes of Health (CA238263)
Article History
Received: 23 December 2021
Accepted: 3 November 2022
First Online: 29 December 2022
Competing interests
: V.A.B. has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako. All the other authors declare no competing interests.